- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Dana Goldman Discusses Determing Value for Breakthrough Therapies
Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.
Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.
For example, there is value in curing a disease because it not only impacts the patient but also anyone the patient may have come in contact with, including caregivers and family members.
“We need to figure out how all these ancillary sources of value are affected and in particular who should pay for them as well,” Dr Goldman says.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
